Enlivex Therapeutics announced the appointment of Andrew Singer to its Board of Directors. Singer brings more than 25 years of experience in biotechnology, corporate finance, mergers and acquisitions, and business strategy from his extensive investment banking and executive management career.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ENLV:
- Enlivex Appoints Andrew Singer to its Board of Directors
- Enlivex, BeiGene enter clinical collaboration agreement
- Enlivex Therapeutics provides business updates on clinical programs
- Enlivex Announces Tislelizumab Clinical Collaboration, Full Year 2022 Financial Results, and Provides Business Updates
- Enlivex Announces Clinical Collaboration to Evaluate Combinations of Allocetra and PD-1 Inhibitor Tislelizumab for Patients with Solid Tumors
